If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPetro Matad Regulatory News (MATD)

Share Price Information for Petro Matad (MATD)

Share Price is delayed by 15 minutes
Get Live Data
1.10    0.00 (0.00%)
Bid:
1.05
Ask:
1.15
Spread: 0.10 (9.524%)
Market Cap: £20.45m
MATD Live PriceLast checked at - London Stock Exchange

Intraday Petro Matad Share Chart

Director/PDMR Shareholding and Total Voting Rights

24 Mar 2017 11:13

RNS Number : 4716A
Petro Matad Limited
24 March 2017
 

24 March 2017

Petro Matad Limited

("Petro Matad" or the "Company")

Directors' Dealings, Issue of Equity and Total Voting Rights

 

Dealings between Concert Party members

Petro Matad announces that on 24 March 2017 Dr Oyungerel Janchiv, a director of Petro Matad, sold 2,500,000 ordinary shares of US$0.01 each in the Company ("Shares") to Petrovis Matad Inc. ("Petrovis"), at 25p per Share. Each of Dr Oyungerel and Petrovis are members of the Petrovis Group Concert Party, as detailed further below.

 

Exercise of Options

Petro Matad further announces that it has issued 429,500 new Shares pursuant to the exercise of options by certain Directors and employees on 24 March 2017. The below table sets out the changes to Directors' shareholdings following the exercise of options:

Director

Options exercised

Exercise price per Share

Resultant shareholding

Percentage holding of enlarged issued share capital

Oyungerel Janchiv*

62,500

£0.11

16,867,946

5.86%

Ridvan Karpuz

75,000

£0.0788

2,021,209

0.70%

Amarzul Tuul

45,000

£0.11

583,334

0.20%

7,000

£0.1975

 

* Dr Oyungerel Janchiv controls more than 20% of Petrovis. Her direct holding in Petro Matad of 16,867,946 Shares (following her share sale to Petrovis and exercise of options) is, for disclosure purposes, aggregated with that of Petrovis under the AIM definition of director's family. The aggregated holding of Dr Oyungerel and Petrovis is 111,552,208 Shares representing 38.74 per cent. of the Company's enlarged issued share capital.

 

Concert Party holding

Following the issue of the new Shares to Dr Oyungerel Janchiv, the Petrovis Group (being Petrovis, its underlying shareholders and their family members) will hold 144,112,822 Shares, representing 50.05 per cent. of the Company's enlarged issued share capital.

 

Application for admission of new Shares

Application has been made for the 429,500 new Shares, which rank pari passu with the Company's existing issued Shares, to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on 30 March 2017.

 

Total Voting Rights

Following Admission, Petro Matad will have 287,924,275 ordinary shares in issue, which will also represent the total number of voting rights in the Company. No Share are held in Treasury. This figure should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Enquiries:

 

Petro Matad Limited

Ridvan Karpuz, CEO +97 670 141 099 / +97 675 751 099

 

NOMAD and Broker

Stockdale Securities Limited

Richard Johnson / David Coaten +44 (0)20 7601 6100

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFZLFLDXFFBBB
Date   Source Headline
25th Jun 20267:00 amRNSFinal results for year ended 31 December 2025
28th May 202612:00 pmRNSResult of AGM
28th May 20267:00 amRNSOperational Update
15th May 20267:00 amRNSNotice of AGM Logistics
30th Apr 20267:00 amRNSNotice of AGM
18th Feb 20267:00 amRNSPetro Matad Operational Update
13th Jan 20267:00 amRNSBoard Changes
12th Dec 20257:00 amRNSOperational Update
10th Dec 20257:00 amRNS-RInvestor Presentation
5th Nov 20257:00 amRNSOperational Update
9th Oct 20257:00 amRNSOperational Update
29th Sep 20257:05 amRNSInterim results for six months ended 30 June 2025
29th Sep 20257:00 amRNSH1 Production Operations and Well Testing Update
24th Sep 20257:00 amRNSOperational Update
26th Aug 20257:00 amRNSOperational Update
30th Jul 20257:00 amRNSOperational Update
23rd Jul 202512:00 pmRNS-RInvestor Presentation
16th Jul 20257:00 amRNSResult of Retail Offer
11th Jul 20257:05 amRNSRetail Offer
11th Jul 20257:00 amRNSResults of Placing and Subscription
10th Jul 20254:35 pmRNSProposed Capital Raising
26th Jun 20254:58 pmRNSFinal results year ended 31 Dec 2024 - Replacement
26th Jun 20257:00 amRNSFinal results for year ended 31 December 2024
18th Jun 20257:00 amRNSProduction Revenue Received
30th May 20257:00 amRNSOperational Update
28th Apr 20257:00 amRNSSignature of Oil Sales Agreement
13th Mar 202510:40 amRNSResult of AGM
13th Mar 20257:00 amRNSOperational Update
28th Feb 20257:00 amRNSNotice of AGM Logistics
14th Feb 20257:00 amRNSNotice of AGM
5th Feb 20257:00 amRNSCertification of Block XX Exploitation Area
16th Jan 20257:00 amRNSOperational Update
14th Nov 20247:00 amRNSOperational Update
25th Oct 20247:00 amRNSProduction startup at Heron-1
22nd Oct 20247:00 amRNSPlanned production startup at Heron-1
7th Oct 20247:00 amRNSOperational Update
1st Oct 20247:07 amRNSHeron-2 drilling results
23rd Sep 20247:00 amRNSSpud of Gobi Bear-1 exploration well
19th Sep 20247:02 amRNSInterim results for six months ended 30 June 2024
19th Sep 20247:00 amRNSHeron-1 operational update
9th Sep 20247:00 amRNSOperational Update – Spud of Heron-2
22nd Aug 20247:00 amRNSOperational Update
23rd Jul 20247:00 amRNSCommencement of Heron-1 Completion Operations
10th Jul 20247:00 amRNSInvestor Presentation & Forward Work Programme
1st Jul 20247:00 amRNSResult of Retail Offer
28th Jun 20247:00 amRNSIssue of equity
26th Jun 20247:00 amRNSRetail Offer
26th Jun 20247:00 amRNSResults of Capital Raise
25th Jun 20244:40 pmRNSProposed fundraise to raise up to USD$8.5 million
19th Jun 20247:00 amRNSFinal results for year ended 31 December 2023

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.